Pfizer (PFE) Tops Q4 EPS by 6c, FY18 EPS Guidance Beats, Sees $15B Repatriation Tax Liability
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Pfizer (PFE) PT Raised to $42 at UBS
January 31, 2018 9:37 AM ESTUBS raised its price target on Pfizer (NYSE: PFE) to $42.00 (from $40.00) while maintaining a Buy rating.
... MorePfizer (PFE) PT Raised to $44 at Bernstein on 4Q Beat; 'Lower than Expected Tax Rate... Decent 2018 Guidance'
January 31, 2018 8:58 AM ESTBernstein raised its price target on Pfizer (NYSE: PFE) to $44.00 (from $43.00) while maintaining a Outperform rating, following the company's fourth quarter earnings report.
Analyst Tim Anderson notes an increased price target on the shares, as PFE reported fourth quarter earnings per share and revenue... More
Pfizer (PFE) PT Raised to $42 at Deutsche Bank Following 4Q
January 31, 2018 7:39 AM ESTDeutsche Bank raised its price target on Pfizer (NYSE: PFE) to $42.00 (from $41.00) while maintaining a Buy rating following 4Q. PFE reported 4Q EPS of $0.62, well above consensus of $0.56. Revenue came in just above estimates, while gross margin was lower and operating expenses were... More
